T1 mapping to characterize heart tissue in common heart diseases
Official title: The Landscape of T1 Mapping for Disease Profiling in a Real-World Cohort
Run by Chinese Academy of Medical Sciences, Fuwai Hospital · NCT07354646 · Data updated 2026-11-12
This project tests whether T1 mapping MRI scans, including dye-free native T1, can define normal and disease-specific heart tissue values for adults with various heart conditions.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | March 1, 2020 |
| Main results expected | December 1, 2026 |
| Study ends | December 1, 2026 |
| Registry record updated | November 9, 2026 |
| Trial ID | NCT07354646 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with guideline-confirmed myocardial diseases such as MI, hypertrophic, dilated, arrhythmogenic cardiomyopathies, myocarditis, infiltrative or other cardiac conditions who can undergo cardiac MRI are ideal candidates.
✕Probably not a fit
Patients who cannot undergo MRI (for example due to incompatible implants), who are under 18, or whose cardiac condition is not represented in the enrolled disease categories may not receive benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational, single-center study will collect cardiac MRI T1 mapping scans from adults with guideline-confirmed myocardial conditions (MI, HCM, DCM, myocarditis, arrhythmogenic cardiomyopathy and other listed diagnoses) at Fuwai Hospital. Imaging will include native (non-contrast) T1 measurements and contrast-enhanced scans to derive extracellular volume (ECV). Investigators will analyze images together with clinical records to create disease-specific reference ranges and to compare the diagnostic performance of native T1 versus ECV. The aim is to produce a real-world spectrum of T1 values that clinicians can apply when interpreting advanced cardiac MRI.
Why it matters
Potential benefit: If successful, clinicians could use clear, disease-specific T1 reference ranges—and possibly dye-free native T1—to diagnose and monitor heart diseases more easily and with less reliance on contrast agents.
How similar studies have gone: T1 mapping and ECV have demonstrated diagnostic value in prior research for many cardiomyopathies, but large real-world reference datasets and direct comparisons of native T1 versus ECV across diverse diseases remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adult patients (≥18 years) with clinically diagnosed myocardial diseases based on current international guidelines. 2. Specific disease categories include: * Cardiomyopathies (HCM, DCM, RCM, ACM) * Infiltrative disorders (cardiac amyloidosis, Fabry disease) * Inflammatory conditions (acute/chronic myocarditis) * Ischemic heart disease (acute/chronic MI) * Valvular heart disease (aortic stenosis) * Arrhythmic conditions (atrial fibrillation) * Metabolic disorders (iron-overload) * Neoplastic conditions (cardiac tumors) * Congenital heart disease * Post-transplant evaluation 3. All diagnoses must be confirmed using established guideline-based criteria: * Echocardiographic parameters meeting disease-specific cutoffs * Cardiac MRI findings consistent with current consensus criteria * Laboratory biomarkers supporting respective diagnoses * Histopathological confirmation when clinically indicated Exclusion Criteria: * Presence of multiple cardiomyopathy diseases or risk factors simultaneously * Contraindications to CMR examination * Poor image quality precluding accurate T1 mapping analysis * Incomplete clinical data for definitive diagnosis confirmation * Pregnancy or lactation * Inability to provide informed consent
Where it's running
-
Fuwai Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Huaying Zhang, Doctor
- Email: zhy_dreamer@163.com
- Phone: 86 13695310578
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Multimodal analysis of heart biopsy samples
This project will take one extra small heart biopsy during a clinically needed procedure to test whether detailed molecular and immune analyses can find disease-specific signatures in adults with cardiomyopathies, myocarditis, cardiac amyloidosis, or after heart transplant.
-
Identifying patients with cardiomyopathy for potential heart transplantation
This study is trying to find new ways to identify and understand cardiomyopathy in patients to better predict if they might need a heart transplant in the future.
-
Registry for patients with non-ischemic cardiomyopathies
This study is collecting information from people with non-ischemic cardiomyopathies to see how to better diagnose and manage their condition and predict potential heart rhythm problems.
-
S-ICD Eligibility Over Time in Arrhythmogenic Cardiomyopathy
This study checks whether adults with arrhythmogenic cardiomyopathy stay eligible for a subcutaneous ICD over 18 months.
-
Risk of malignant arrhythmias after acute coronary syndrome
This study tracks how often dangerous heart rhythms occur in adults admitted for ACS and looks for patterns that might predict them.
-
Smartphone AI help for prehospital ECG readings
This study tests whether using a smartphone AI (GPT-4o) to help prehospital providers read 12-lead ECGs improves accuracy in diagnosing acute coronary syndromes and related conditions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.